.Organisation / Company: CEU San Pablo UniversityDepartment: Pharmacy Faculty Laboratory Institute for Applied Molecular Medicine Nemesio Díez (IMMA-ND)Selected candidates will be provided with special assistance for proposal writing and development.
Our University has been beneficiary of 7 MSCA PF since 2017, including one MSCA-PF with an evaluation of 100/100 in 2021.We look for researchers interested in studying the molecular determinants underlying the immunopathologic immune response associated with Influenza virus and respiratory bacteria coinfections, supervised by Dr. Estanislao Nistal Villán - https://orcid.Org/0000-0003-2458-8833 .Dr.
Nistal-Villán's Research Group is located at the Institute for Applied Molecular Medicine Nemesio Díez (IMMA-ND) at USP-CEU.
The group is composed of the PI, two Postdoctoral researchers, three PhD students, one technician, and a Master's student.
Eventually, undergraduate students collaborate with us.
The Group works together with Groups at the National Center for Microbiology at Instituto de Salud Carlos III (CNM-ISCIII), Fundación Vithas, National Center for Biotechnology (CNB-CSIC), and Hospital 12 de Octubre in Madrid.
International collaborations include the Microbiology Department of Icahn School of Medicine at Mount Sinai in New York, and the Department of Microbiology and Molecular Medicine at the University of Geneva.Our group is interested in a main area of research, the innate immune response against Influenza virus and respiratory bacteria coinfections.
We have a strong background in studying the cell signaling and regulation mechanisms that control the antiviral response including the type I IFNs and proinflammatory cytokines.
We study antiviral response mechanisms and alternative inducers and repressors of type I IFN and proinflammatory cytokines.Relevant publications in the area of research include:Influenza A virus infection alters the resistance profile of gut microbiota to clinically relevant antibiotics.
Microbiol Spectr.
2024.Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis.
Int J Infect Dis.
2023.Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections.
Cell Reports.
2022.Broad virus inactivation using inorganic micro/nano-particulate materials.
Materials Today Bio.
2021.Linking the expression of therapeutic genes to unfolded protein response: A new option for anti-HBV gene therapy.
Journal of Hepatology.
2020.Research Project Description:Despite multiple advances in the knowledge of the virus pathology, the improvement of health conditions, and annual influenza and pneumococcus vaccination campaigns, influenza-related secondary bacterial infections, especially in patients of advanced age, cause thousands of deaths every year in Europe.
The causes underlying the complications of these superinfections require further analysis.Dr